In the treatment landscape of hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer, cyclin-dependent kinase (CDK) inhibitors have emerged as one of the most transformative targeted therapies over the past decade.

Representative CDK4/6 inhibitors such as Palbociclib, Ribociclib, and Abemaciclib have significantly prolonged progression-free survival (PFS) and reshaped the paradigm of endocrine combination therapy.

However, with broader clinical use, resistance has gradually become a common challenge. A growing body of evidence suggests that compensatory activation of CDK2 represents one of the key mechanisms underlying resistance to CDK4/6 inhibitors.

In this context, dual-target strategies simultaneously inhibiting CDK4 and CDK2 are emerging as a promising approach to overcome therapeutic bottlenecks. Meanwhile, global pharmaceutical distributor DengYueMed is accelerating access to these cutting-edge therapies across different markets.

Limitations of CDK4/6 Inhibitors: Resistance as an Ongoing Challenge

CDK4/6 inhibitors suppress tumor proliferation by arresting the cell cycle at the G1 phase, thereby preventing entry into DNA replication.

However, this mechanism does not constitute a complete blockade. Tumor cells can upregulate the Cyclin E/CDK2 pathway, bypass the G1/S checkpoint, and restore cell cycle progression.

This “bypass activation” mechanism implies that even when CDK4/6 is effectively inhibited, CDK2 can still drive continued proliferation, ultimately leading to acquired resistance. This also explains why disease progression eventually occurs in most patients after an initial period of response.

At the same time, selective CDK2 inhibition alone is unlikely to achieve optimal efficacy, as CDK4 can still initiate cell cycle progression. Mechanistically, targeting a single node is insufficient to fully suppress tumor growth.

CDK2/4 Dual Inhibition: From Mechanistic Rationale to Clinical Potential

The core concept of CDK2/4 dual inhibition lies in simultaneously blocking two critical nodes of the cell cycle: initiation and progression. CDK4 drives G1 phase entry, while CDK2 governs the transition from G1 to S phase. Dual inhibition therefore enables a more comprehensive suppression of tumor proliferation.

This strategy offers clear clinical potential.

On one hand, CDK2/4 dual inhibition directly targets the primary escape pathway associated with CDK4/6 resistance, making it particularly relevant for patients who have progressed on endocrine therapy or CDK4/6 inhibitors.

On the other hand, by covering key phases of the cell cycle, this approach may also provide benefits in difficult-to-treat populations, including those with visceral or liver metastases.

From a safety perspective, next-generation molecules are being designed with improved selectivity—such as reduced CDK6 inhibition—to potentially mitigate hematologic toxicities and improve long-term tolerability.

Global Pipeline: Key CDK2/4 (±CDK6) Inhibitors

Culmerciclib (TQB3616)

Culmerciclib, developed by Chia Tai Tianqing, is currently the first publicly reported CDK2/4/6 inhibitor approved for marketing (China, 2025), marking the entry of multi-target CDK inhibition into the commercial stage.

Mechanistically, Culmerciclib inhibits not only CDK4/6-mediated G1 initiation but also CDK2-driven G1/S transition, enabling a more complete blockade of the cell cycle. This triple-target coverage is particularly relevant in patients with Cyclin E overexpression or CDK4/6 resistance.

In a pivotal Phase III study (in combination with fulvestrant for HR+/HER2- advanced breast cancer), median PFS reached 16.6 months compared with 7.5 months in the control group, corresponding to a ~64% reduction in the risk of disease progression or death. The objective response rate (ORR) was 40.2%.

In terms of safety, the incidence of grade ≥3 neutropenia was approximately 24.7%, with no reported febrile neutropenia, suggesting a manageable safety profile.

Clinically, Culmerciclib may serve both as a first-line combination option and as a potential treatment for patients who have progressed on prior CDK4/6 inhibitors, representing a significant milestone in the field.

RGT-419B (GDC-419B)

RGT-419B was originally developed by Qilu Ruige and later licensed to Roche and its subsidiary Genentech for global development. It is currently in Phase I/II clinical trials in both China and the United States.

This molecule is characterized by enhanced CDK2 inhibitory activity. Structurally optimized from existing CDK inhibitor scaffolds, it retains CDK4/6 activity while strengthening CDK2 inhibition, aiming to more effectively address Cyclin E/CDK2-driven resistance.

From a development perspective, RGT-419B reflects a broader shift in the CDK field—from a CDK4/6-centric approach toward positioning CDK2 as a critical therapeutic target.

Although still in early-stage development, its global licensing underscores its potential. Future clinical data will be crucial in determining whether enhanced CDK2 inhibition translates into meaningful clinical benefit.

PF-06873600 (Ebvaciclib)

PF-06873600 (Ebvaciclib), developed by Pfizer, is a triple CDK2/4/6 inhibitor derived from its well-known CDK4/6 inhibitor Palbociclib.

Preclinically, the compound demonstrated nanomolar inhibitory activity against CDK2, CDK4, and CDK6, effectively inducing cell cycle arrest and promoting apoptosis.

However, despite showing preliminary antitumor activity in Phase I studies, the program was ultimately discontinued due to an inability to achieve an optimal balance between efficacy and safety.

This case highlights an important industry insight: broader target coverage does not necessarily translate into superior outcomes. Insufficient selectivity or a narrow therapeutic window may limit clinical applicability. Achieving a precise balance between CDK2 and CDK4 inhibition remains a key challenge in drug design.

NUV-422

NUV-422, developed by Nuvation Bio, is another CDK2/4/6 inhibitor that entered clinical development.

While early studies explored its safety and preliminary efficacy across multiple solid tumors, it failed to demonstrate a clear clinical benefit signal and showed suboptimal safety, leading to discontinuation.

Together with PF-06873600, this case reinforces a central challenge in CDK2-targeted therapy: the difficulty lies not in achieving inhibition, but in maintaining effective and tolerable inhibition that translates into clinical benefit.

TYK-0540

TYK-0540, developed by Tongyuan Kang Pharmaceutical, is one of the few investigational agents specifically designed as a CDK2/4 dual inhibitor. It is currently in Phase I/II trials in China.

Unlike triple inhibitors, TYK-0540 adopts a “CDK6-sparing” strategy—retaining CDK2 and CDK4 inhibition while minimizing CDK6 activity. This approach is based on clinical observations suggesting that CDK6 inhibition is associated with hematologic toxicity, particularly neutropenia.

The goal of this design is to preserve antitumor efficacy while reducing hematologic adverse events and improving long-term tolerability.

The ongoing clinical studies will help determine whether dual inhibition offers advantages over triple inhibition in resistant breast cancer populations.

INV-6452

INV-6452, developed by Ionova Life Science, entered clinical trials in 2025 and represents another CDK2/4 dual inhibitor candidate.

It is primarily being developed for HR+/HER2- advanced breast cancer, particularly in patients who have failed endocrine therapy or developed resistance to CDK4/6 inhibitors.

Its design focuses on simultaneously inhibiting CDK2 and CDK4 to achieve vertical blockade of cell cycle signaling.

Although clinical data remain limited, its advancement reflects continued industry confidence in the dual-target strategy. Future results will be critical in defining its clinical positioning.

China Innovation and Globalization Trends

The rapid evolution of CDK2/4 inhibitors reflects a broader structural shift in China’s pharmaceutical innovation ecosystem—from fast-follow strategies toward true first-in-class innovation.

While early efforts focused on optimizing validated targets, current approaches are increasingly driven by resistance biology, leading to the development of multi-target strategies such as CDK2/4 and CDK2/4/6 inhibition.

The approval of Culmerciclib highlights China’s growing capability in achieving original breakthroughs in the cell cycle field.

At the same time, advances in molecular design and selectivity optimization are enabling Chinese companies to compete more effectively on a global stage.

From a globalization perspective, Chinese innovation is increasingly integrated into the global R&D system.

Overall, as more differentiated CDK2/4 inhibitors advance into late-stage clinical development, China is expected to play a more prominent role in shaping the future landscape of oncology therapeutics.

Conclusion

At present, the key questions for CDK2/4 inhibitors remain whether they can significantly extend survival in CDK4/6-resistant populations and whether they offer a tolerable safety profile for long-term use.

Overall, CDK2/4 dual inhibition represents a mechanistically grounded and promising strategy to address resistance in HR+/HER2- breast cancer.

By simultaneously targeting critical nodes of the cell cycle, this approach offers a more comprehensive therapeutic framework and has already demonstrated early clinical potential.

As more innovative therapies enter global markets—and with distribution networks such as DengYueMed continuing to expand access—these next-generation treatments are expected to reach patients more efficiently worldwide, further advancing precision oncology and global treatment accessibility.